Life-threatening events in patients with LQT3 on and off beta-blockers: Insights from a case series
The efficacy of beta-blocker in type 3 long QT syndrome (LQT3) remains uncertain, with conflicting results in the literature.1,2 Wilde et al1 reported benefit in women, but this was not confirmed in a French cohort.2 This discrepancy has raised concerns that confounding by indication—that is, the preferential prescription of beta-blockers to the most severely affected patients—might partly explain the apparent lack of benefit observed in some studies. To explore this hypothesis, we conducted a detailed evaluation of LQT3 patients who experienced life-threatening events (LTEs), either on or off beta-blocker therapy.
Authors
- Vincent Probst (ORCID: https://orcid.org/0000-0002-5492-8619)
- Alexis Hermida (ORCID: https://orcid.org/0000-0003-2392-3759)
- Isabelle Denjoy (ORCID: https://orcid.org/0000-0002-1786-9461)
- Fabrice Extramiana (ORCID: https://orcid.org/0000-0001-8123-4842)
- Adrien Bloch
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Sorbonne Université (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut du Thorax (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Université de Picardie Jules Verne (FR)
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.hroo.2025.11.005
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00